PATENT COOPERATION TREATY

PCT/JP2003/015009

Translation

Rec'd PCT/PTO 11 OCT 2005

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

	·		
Applicant's or agent's file reference FP149OP1667	FOR FURTHER AC	TION	See Form PCT/IPEA/416
International application No.	International filing date	(day/month/year)	Priority date (day/month/year)
PCT/JP2003/015009	25 November 200	3 (25.11.2003)	24 February 2003 (24.02.2003)
International Patent Classification (IPC) or n A61K 38/44, A61P 7/00, 7/02, 9	ational classification and /10, 13/12, 29/00, 31/1	IPC 16, 43/00, A23L 1/3	30, A23K 1/16
Applicant MC	RINAGA MILK IN	DUSTRY CO., L	.TD.
This report is the international prelin Authority under Article 35 and trans	minary examination repo smitted to the applicant a	rt, established by this coording to Article 3	s International Preliminary Examining 6.
2. This REPORT consists of a total of	4 sheets,	including this cover s	sheet.
3. This report is also accompanied by			
a. (sent to the applicant and	d to the International Bur	reau) a total of	sheets, as follows:
sheets of the desc and/or sheets cor Administrative In	itaining rectifications aut	awings which have b horized by this Auth	peen amended and are the basis of this report ority (see Rule 70.16 and Section 607 of the
sheets which sup beyond the discl Supplemental Bo	osure in the international	t which this Authorit application as filed,	y considers contain an amendment that goes as indicated in item 4 of Box No. I and the
	, contain ndicated in the Supplement	ning a sequence listi	ype and number of electronic carrier(s)) ng and/or tables related thereto, in computer to Sequence Listing (see Section 802 of the
This report contains indications rel	ating to the following iter	ms:	
Box No. I Basis of the r	eport		
Box No. II Priority			
Box No. III Non-establish	hment of opinion with re	gard to novelty, inve	ntive step and industrial applicability
Box No. IV Lack of unity	of invention		
	tement under Article 35(explanations supporting		velty, inventive step or industrial applicability;
Box No. VI Certain docu			•
Box No. VII Certain defec	cts in the international ap	plication	
Box No. VIII Certain obse	rvations on the internatio	nal application	
Data of submission of the descent		Date of completion	of this report
Date of submission of the demand		-	
25 March 2004 (25.03	3.2004)		0 July 2004 (20.07.2004)
Name and mailing address of the IPEA/JP		Authorized officer	
Facsimile No		Telephone No.	

International application No.

PCT/JP2003/015009

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Box No.	Basis of the report
	egard to the language, this report is based on the international application in the language in which it was filed, unless rise indicated under this item.
	This report is based on translations from the original language into the following language, which is language of a translation furnished for the purpose of:
	international search (under Rules 12.3 and 23.1(b))
	publication of the international application (under Rule 12.4)
	international preliminary examination (under Rules 55.2 and/or 55.3)
	,,
furnis	regard to the elements of the international application, this report is based on (replacement sheets which have been the to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" re not annexed to this report):
	The international application as originally filed/furnished
🗀	the description: pages , as originally filed/furnished
	pages*
\sqcup	the claims:
	pages*, as originally filed/furnished pages*, as amended (together with any statement) under Article 19
	pages*, as amended (together with any statement) under Article 19 pages*, as amended (together with any statement) under Article 19
	nages* received by this Authority on
	the drawings:
	pages, as originally filed/furnished
	pages* received by this Authority on
l	pages* received by this Authority on
	a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
3.	The amendments have resulted in the cancellation of:
	the description, pages
	the claims, Nos.
1	the drawings, sheets/figs
	the sequence listing (specify):
	any table(s) related to sequence listing (specify):
4.	This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
	the claims, Nos.
1	the drawings, sheets/figs
1	the sequence listing (specify):
1	any table(s) related to sequence listing (specify):
1	
* If ite	n 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/JP03/15009

Box No. I	II Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	
	stions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially have not been examined in respect of:	ally
	the entire international application.	
\boxtimes	claims Nos	
becaus	se:	
\boxtimes	the said international application, or the said claims Nos. 7, 8 relate to the following subject matter which does not require an international preliminary examination (specify):	-
Th	he subject matters of claims 7 and 8 relate to a method for treatment of the human body by therapy.	
		1
	the description, claims or drawings (indicate particular elements below) or said claims Nosare so unclear that no meaningful opinion could be formed (specify):	-
	\$ 1 \\1 3h	
	the claims, or said claims Nos are so inadequately supporte	d
	by the description that no meaningful opinion could be formed.	
\boxtimes	no international search report has been established for said claims Nos	. •
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the	
	Administrative Instructions in that:	
	the written form has not been furnished	
	does not comply with the standard	
	the computer readable form has not been furnished	
	does not comply with the standard	
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply	with
	the technical requirements provided for in Annex C-bis of the Administrative Instructions.	
	see Supplemental Box for further details.	

International application No.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

PCT/JP03/15009

Statement Novelty (N) Claims Claims No Inventive step (IS) Claims Claims 1-6 YES Claims NO Industrial applicability (IA) Claims 1-6 YES Claims NO Citations and explanations (Rule 70.7) Cocument 1: Infection and Immunity, October 2000, Vol. 68, No. 10, pages 5816-5823 Cocument 2: JP, 5-9124, A (The Calpis Co., Ltd.), 19 January, 1993 (19.01.93) Cocument 3: JP, 6-501453, A (Universite Libre de Bruxelles), 17 February, 1994 (17.02.94), & WO, 92-014-10 Cocument 4: JP, 8-169846, A (Chuzo Kishimoto), 2 July, 1996 (02.07.96), & EP, 791359, A1 Cocument 5: JP, 2002-507224, A (Universidad Complutense de Madrid), 5 March, 2002 (05.03.02), & EP, 102542, A1 Laims 1-6 The subject matters of claims 1-6 appear to be novel and to involve an inventive step in view of cocuments 1 and 2 cited in the ISR and documents 3-5 that are patent family members of the documents cite is ISR. Documents 1-5 neither describe nor suggest that Lactoperoxidase has interleukin 6 production inhibited citivity or can be used for prevention and/or therapy of the diseases particularly stated in the claims.		nder Article 35(2) with regions supporting such state	gard to novelty, inventive step or industria	l applicability;
Claims I-6 YES NO Citations and explanations (Rule 70.7) Coument 1: Infection and Immunity, October 2000, Vol. 68, No. 10, pages 5816-5823 Coument 2: JP, 5-9124, A (The Calpis Co., Ltd.), 19 January, 1993 (19.01.93) Coument 3: JP, 6-501453, A (Universite Libre de Bruxelles), 17 February, 1994 (17.02.94), & WO, 92-014-10 Coument 4: JP, 8-169846, A (Chuzo Kishimoto), 2 July, 1996 (02.07.96), & EP, 791359, A1 Coument 5: JP, 2002-507224, A (Universidad Complutense de Madrid), 5 March, 2002 (05.03.02), & EP, 102542, A1 Laims 1-6 The subject matters of claims 1-6 appear to be novel and to involve an inventive step in view of couments 1 and 2 cited in the ISR and documents 3-5 that are patent family members of the documents cite is ISR. Documents 1-5 neither describe nor suggest that Lactoperoxidase has interleukin 6 production inhibitor in the interleukin 6 production inhibitor interleukin 6 producti	Statement			
Industrial applicability (IA) Claims Claims 1-6 YES NO Industrial applicability (IA) Claims 1-6 YES Claims NO Citations and explanations (Rule 70.7) Coument 1: Infection and Immunity, October 2000, Vol. 68, No. 10, pages 5816-5823 Coument 2: JP, 5-9124, A (The Calpis Co., Ltd.), 19 January, 1993 (19.01.93) Coument 3: JP, 6-501453, A (Universite Libre de Bruxelles), 17 February, 1994 (17.02.94), & WO, 92-014-19 Coument 4: JP, 8-169846, A (Chuzo Kishimoto), 2 July, 1996 (02.07.96), & EP, 791359, A1 Coument 5: JP, 2002-507224, A (Universidad Complutense de Madrid), 5 March, 2002 (05.03.02), & EP, 2002542, A1 Claims 1-6 The subject matters of claims 1-6 appear to be novel and to involve an inventive step in view of couments 1 and 2 cited in the ISR and documents 3-5 that are patent family members of the documents cite e ISR. Documents 1-5 neither describe nor suggest that Lactoperoxidase has interleukin 6 production inhibitor.	Novelty (N)	Claims	1-6	
Claims Claims Claims 1-6 YES Claims NO Citations and explanations (Rule 70.7) Citations and explanations (Rule 70.7) Cocument 1: Infection and Immunity, October 2000, Vol. 68, No. 10, pages 5816-5823 Cocument 2: JP, 5-9124, A (The Calpis Co., Ltd.), 19 January, 1993 (19.01.93) Cocument 3: JP, 6-501453, A (Universite Libre de Bruxelles), 17 February, 1994 (17.02.94), & WO, 92-014-1 Cocument 4: JP, 8-169846, A (Chuzo Kishimoto), 2 July, 1996 (02.07.96), & EP, 791359, A1 Cocument 5: JP, 2002-507224, A (Universidad Complutense de Madrid), 5 March, 2002 (05.03.02), & EP, 202542, A1 Claims 1-6 The subject matters of claims 1-6 appear to be novel and to involve an inventive step in view of cuments 1 and 2 cited in the ISR and documents 3-5 that are patent family members of the documents cite e ISR. Documents 1-5 neither describe nor suggest that Lactoperoxidase has interleukin 6 production inhibitors.		Claims		NO
Industrial applicability (IA) Claims 1-6 YES Claims NO Citations and explanations (Rule 70.7) Cocument 1: Infection and Immunity, October 2000, Vol. 68, No. 10, pages 5816-5823 Cocument 2: JP, 5-9124, A (The Calpis Co., Ltd.), 19 January, 1993 (19.01.93) Cocument 3: JP, 6-501453, A (Universite Libre de Bruxelles), 17 February, 1994 (17.02.94), & WO, 92-014-10 Cocument 4: JP, 8-169846, A (Chuzo Kishimoto), 2 July, 1996 (02.07.96), & EP, 791359, A1 Cocument 5: JP, 2002-507224, A (Universidad Complutense de Madrid), 5 March, 2002 (05.03.02), & EP, 202542, A1 Itaims 1-6 The subject matters of claims 1-6 appear to be novel and to involve an inventive step in view of couments 1 and 2 cited in the ISR and documents 3-5 that are patent family members of the documents cite e ISR. Documents 1-5 neither describe nor suggest that Lactoperoxidase has interleukin 6 production inhibitory.	Inventive step (IS)	Claims	1-6	YES
Claims Claims No Citations and explanations (Rule 70.7) Cournent 1: Infection and Immunity, October 2000, Vol. 68, No. 10, pages 5816-5823 Cournent 2: JP, 5-9124, A (The Calpis Co., Ltd.), 19 January, 1993 (19.01.93) Cournent 3: JP, 6-501453, A (Universite Libre de Bruxelles), 17 February, 1994 (17.02.94), & WO, 92-014-10 Cournent 4: JP, 8-169846, A (Chuzo Kishimoto), 2 July, 1996 (02.07.96), & EP, 791359, A1 Cournent 5: JP, 2002-507224, A (Universidad Complutense de Madrid), 5 March, 2002 (05.03.02), & EP, 1002542, A1 Claims 1-6 The subject matters of claims 1-6 appear to be novel and to involve an inventive step in view of cournents 1 and 2 cited in the ISR and documents 3-5 that are patent family members of the documents cite is ISR. Documents 1-5 neither describe nor suggest that Lactoperoxidase has interleukin 6 production inhibitors.		Claims		NO NO
Citations and explanations (Rule 70.7) comment 1: Infection and Immunity, October 2000, Vol. 68, No. 10, pages 5816-5823 comment 2: JP, 5-9124, A (The Calpis Co., Ltd.), 19 January, 1993 (19.01.93) comment 3: JP, 6-501453, A (Universite Libre de Bruxelles), 17 February, 1994 (17.02.94), & WO, 92-014 comment 4: JP, 8-169846, A (Chuzo Kishimoto), 2 July, 1996 (02.07.96), & EP, 791359, A1 comment 5: JP, 2002-507224, A (Universidad Complutense de Madrid), 5 March, 2002 (05.03.02), & EP, 202542, A1 laims 1-6 The subject matters of claims 1-6 appear to be novel and to involve an inventive step in view of comments 1 and 2 cited in the ISR and documents 3-5 that are patent family members of the documents cite is in the ISR. Documents 1-5 neither describe nor suggest that Lactoperoxidase has interleukin 6 production inhibitors.	Industrial applicability (IA)	Claims	1-6	YES
ocument 1: Infection and Immunity, October 2000, Vol. 68, No. 10, pages 5816-5823 ocument 2: JP, 5-9124, A (The Calpis Co., Ltd.), 19 January, 1993 (19.01.93) ocument 3: JP, 6-501453, A (Universite Libre de Bruxelles), 17 February, 1994 (17.02.94), & WO, 92-014 ocument 4: JP, 8-169846, A (Chuzo Kishimoto), 2 July, 1996 (02.07.96), & EP, 791359, A1 ocument 5: JP, 2002-507224, A (Universidad Complutense de Madrid), 5 March, 2002 (05.03.02), & EP, 002542, A1 laims 1-6 The subject matters of claims 1-6 appear to be novel and to involve an inventive step in view of ocuments 1 and 2 cited in the ISR and documents 3-5 that are patent family members of the documents cite e ISR. Documents 1-5 neither describe nor suggest that Lactoperoxidase has interleukin 6 production inhibitory.		Claims		МО
	bocument 1: Infection and Important 2: JP, 5-9124, A (The focument 3: JP, 6-501453, A (Infocument 4: JP, 8-169846, A (focument 5: JP, 2002-507224, 202542, A1) laims 1-6 The subject matters of cluments 1 and 2 cited in the e ISR. Documents 1-5 neither described in the company of the subject matter of the experiments 1 and 2 cited in the experiments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the experiments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the company of the subject matters of cluments 1-5 neither described in the cluments 1-5 neither desc	nunity, October 2000, Note Calpis Co., Ltd.), 19 Universite Libre de Brache (Chuzo Kishimoto), 2 J A (Universidad Comparisms 1-6 appear to be 1 ISR and documents 3-3 describe nor suggest tha	January, 1993 (19.01.93) uxelles), 17 February, 1994 (17.02.9 uly, 1996 (02.07.96), & EP, 791359 lutense de Madrid), 5 March, 2002 (novel and to involve an inventive ste 5 that are patent family members of	, A1 05.03.02), & EP, p in view of the documents cite
				·
				·
				·
				·
				·